BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Fish and Richardson
Boehringer Ingelheim
Teva
Fuji
Dow
Novartis
US Army
US Department of Justice
AstraZeneca

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,067,551

« Back to Dashboard

Which drugs does patent 7,067,551 protect, and when does it expire?

Patent 7,067,551 protects FARYDAK and is included in one NDA.

This patent has forty-three patent family members in thirty-three countries.
Summary for Patent: 7,067,551
Title:Deacetylase inhibitors
Abstract: The present invention provides hydroxamate compounds which are deacetylase inhibitors. The compounds are suitable for pharmaceutical compositions having anti-proliferative properties.
Inventor(s): Remiszewski; Stacy W (Washington Township, NJ), Bair; Kenneth W (Mountain Lakes, NJ), Versace; Richard W (Wanaque, NJ), Perez; Lawrence B (Hackettstown, NJ), Green; Michael A (Easton, PA), Sambucetti; Lidia C (Pacifica, CA), Sharma; Sushil (West Orange, NJ)
Assignee: Novartis AG (Basel, CH)
Application Number:10/984,501
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,067,551

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-001 Feb 23, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE ➤ Subscribe
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-002 Feb 23, 2015 RX Yes No ➤ Subscribe ➤ Subscribe TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE ➤ Subscribe
Novartis Pharms Corp FARYDAK panobinostat lactate CAPSULE;ORAL 205353-003 Feb 23, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,067,551

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,552,065 Deacetylase inhibitors ➤ Subscribe
6,833,384 Deacetylase inhibitors ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,067,551

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035057 ➤ Subscribe
Austria 376999 ➤ Subscribe
Australia 2001282129 ➤ Subscribe
Australia 8212901 ➤ Subscribe
Brazil 0113669 ➤ Subscribe
Brazil PI0113669 ➤ Subscribe
Canada 2420899 ➤ Subscribe
China 1300110 ➤ Subscribe
China 1450991 ➤ Subscribe
Cyprus 1107839 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Healthtrust
Chubb
Boehringer Ingelheim
McKesson
Colorcon
Deloitte
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot